Sakar Healthcare Limited has informed the Exchange about Investor Presentation
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sakar Healthcare reported strong Q4FY26 results with revenue of ₹7,110 lakhs, up 42% YoY, driven by oncology-led growth and new market authorizations. EBITDA surged 67% to ₹2,624 lakhs with margin expanding to 37%, while PAT jumped 91% to ₹1,102 lakhs at a 16% margin. For FY26, revenue reached ₹25,174 lakhs (up 42%) and PAT hit ₹3,048 lakhs (up 74%). The company has developed 55 oncology molecules with 32 dossiers ready for launch, 12 Marketing Authorizations granted, and 60+ business contracts completed. Technology transfer projects are ongoing with major partners including Accord-Intas, Torrent-UK, Emcure, Glenmark, and Zydus. Debt-to-equity ratio improved significantly to 0.2x from 0.7x in FY22.
Strong execution in oncology with improving margins and a robust pipeline of 32 ready-to-launch dossiers positions the company well for FY27 growth. The improving profitability metrics and deleveraged balance sheet enhance shareholder confidence.